Abstract
Coronaviruses (CoV), discovered after 1960, caused human life-threatening outbreaks. SARS-CoV2, which appeared in Wuhan, China in December 2019, causing Severe Acute Respiratory Syndrome and has different features than other coronaviruses, has been determined and the disease caused by the virus has been called "Coronavirus Disease-2019" (COVID-19). This disease activates both the natural and acquired immune system. The cytokin storm, in which blood levels of proinflammatory cytokines are detected excessively high is developing and the uncontrolled inflammatory response causes local and systemic tissue damages. Although a spesific drug has not been found yet, the medications currently in use for other indications, whose pharmacokinetic- pharmacodynamic properties and toxic doses are already known; are included in the treatment practice of COVID-19. These drugs affect the entry of the virus into the cell and its intracellular distribution. They also have anti-inflammatory and immunomodulating effects too. Therefore, we think that Proton Pump Inhibitors (PPI's) with similar mechanisms of action may also be involved in COVID-19 treatment and prophylaxis.
References
May 1, 1992·Gut·J H Wandall
Apr 1, 1991·Journal of Virology·T M GallagherM J Buchmeier
Jun 1, 1990·Journal of Virology·L S SturmanK V Holmes
Jan 1, 1989·Advances in Virus Research·M Marsh, A Helenius
May 1, 1999·Antimicrobial Agents and Chemotherapy·T Skinner-Adams, T M Davis
Nov 21, 2002·Experimental Cell Research·Donatienne TytecaPierre J Courtoy
May 14, 2004·Journal of Virology·Zhi-Yong YangGary J Nabel
Oct 6, 2005·Pediatric Surgery International·Unal BiçakçiFerit Bernay
May 23, 2006·Biochemical and Biophysical Research Communications·Jan C BeckerThorsten Pohle
Jan 25, 2008·The European Respiratory Journal·Q YeU Costabel
Jan 20, 2009·Lupus·M R Namazi
May 28, 2009·Science in China. Series C, Life Sciences·Hongliang Wang, Chengyu Jiang
Dec 17, 2009·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Tsuneyuki UbagaiYasuo Ono
Sep 25, 2012·Expert Opinion on Drug Metabolism & Toxicology·Dion R BrocksRaj S Padwal
May 17, 2013·Journal of Virology·Raoul J de GrootJohn Ziebuhr
Aug 5, 2014·Virulence·Cheston B Cunha, Steven M Opal
Feb 20, 2015·The Journal of Antimicrobial Chemotherapy·Md Abdul Alim Al-Bari
May 21, 2015·Arthritis & Rheumatology·M JallouliUNKNOWN Plaquenil Lupus Systemic Study Group
Feb 12, 2017·Frontiers in Pharmacology·Christina NelsonYohannes T Ghebre
Jun 6, 2018·Frontiers in Pharmacology·Yohannes T Ghebre
Jul 6, 2019·Lupus Science & Medicine·Donald E ThomasMichelle A Petri
Sep 20, 2019·PloS One·Christine L HammondCollynn F Woeller
Dec 19, 2019·Frontiers in Microbiology·Martin MichaelisJindrich Cinatl
Jan 28, 2020·Lancet·Chaolin HuangBin Cao
Feb 9, 2020·Nature Reviews. Rheumatology·Eva Schrezenmeier, Thomas Dörner
Feb 14, 2020·Tropical Medicine & International Health : TM & IH·Thirumalaisamy P Velavan, Christian G Meyer
Apr 11, 2020·Nature Reviews. Immunology·Xuetao Cao
Apr 17, 2020·Postgraduate Medical Journal·Neeraj Sinha, Galit Balayla
Apr 18, 2020·Clinical Pharmacology and Therapeutics·Bharat DamleBrian Corrigan
Citations
Sep 3, 2020·Drug Research·Avik RayBalakrishnan Sadasivam
Aug 12, 2020·Clinical Drug Investigation·Bruno CharpiatMichel Tod
Jan 8, 2021·Curēus·Vinod RustgiReynold Panettieri
Feb 13, 2021·Journal of Inflammation Research·Xiao-Yu ZhangLiang Chen
Feb 20, 2021·Clinical Drug Investigation·Jan HomolakVladimir Trkulja
May 11, 2021·World Journal of Clinical Cases·Maddalena ZippiWandong Hong
Jun 1, 2021·Japanese Journal of Infectious Diseases·Cunye YanQin Zhou
Sep 4, 2021·International Microbiology : the Official Journal of the Spanish Society for Microbiology·Taciéli Fagundes da RosaRosmari Hörner
Oct 12, 2020·Digestive Diseases·Richard H HuntGwilym J Webb